Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Synthetic Biologics: First six participants dosed in Phase 1a trial of SYN-020 » 07:04
04/01/21
04/01
07:04
04/01/21
07:04
SYN

Synthetic Biologics

$0.67 /

-0.0042 (-0.62%)

Synthetic Biologics…

Synthetic Biologics announced that enrollment has commenced and six study participants were dosed in a Phase 1a single-ascending dose clinical trial of SYN-020 intestinal alkaline phosphatase. The Phase 1a study, which is now underway at Spaulding Clinical Research of West Bend, WI, is designed to evaluate safety, tolerability and pharmacokinetics of four single-ascending doses of oral SYN-020 in healthy volunteers. In all, up to 24 healthy adult volunteers will be enrolled into four cohorts that will run sequentially, all of which will receive oral SYN-020. During the third quarter, a topline data readout is expected to be reported and a multiple-ascending dose study of SYN-020 is planned to begin.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.67 /

-0.0042 (-0.62%)

SYN Synthetic Biologics
$0.67 /

-0.0042 (-0.62%)

03/12/21 Maxim
Synthetic Biologics upgraded to Buy from Hold at Maxim
03/12/21 Maxim
Synthetic Biologics upgraded to Buy from Hold at Maxim
10/02/20 Maxim
Synthetic Biologics downgraded to Hold from Buy at Maxim
06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
SYN Synthetic Biologics
$0.67 /

-0.0042 (-0.62%)

Upgrade
Synthetic Biologics upgraded to Buy from Hold at Maxim » 09:20
03/12/21
03/12
09:20
03/12/21
09:20
SYN

Synthetic Biologics

$0.70 /

+0.0338 (+5.04%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy upgraded Synthetic Biologics to Buy from Hold with a $2.50 price target. The analyst is citing the company's progress in aGvHD and Celiac indications while also exploring additional programs. McCarthy adds that Synthetic Biologics' $60M capital raise this year should leave it with enough capital to continue operations well into 2023.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.70 /

+0.0338 (+5.04%)

SYN Synthetic Biologics
$0.70 /

+0.0338 (+5.04%)

03/12/21 Maxim
Synthetic Biologics upgraded to Buy from Hold at Maxim
10/02/20 Maxim
Synthetic Biologics downgraded to Hold from Buy at Maxim
06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
05/06/20 Alliance Global Partners
Synthetic Biologics price target lowered to $1.25 from $2.25 at Alliance Global
SYN Synthetic Biologics
$0.70 /

+0.0338 (+5.04%)

Upgrade
Synthetic Biologics upgraded to Buy from Hold at Maxim » 09:16
03/12/21
03/12
09:16
03/12/21
09:16
SYN

Synthetic Biologics

$0.70 /

+0.0338 (+5.04%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy upgraded Synthetic Biologics to Buy from Hold with a $2.50 price target.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.70 /

+0.0338 (+5.04%)

SYN Synthetic Biologics
$0.70 /

+0.0338 (+5.04%)

10/02/20 Maxim
Synthetic Biologics downgraded to Hold from Buy at Maxim
06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
05/06/20 Alliance Global Partners
Synthetic Biologics price target lowered to $1.25 from $2.25 at Alliance Global
SYN Synthetic Biologics
$0.70 /

+0.0338 (+5.04%)

Over a month ago
Hot Stocks
Synthetic Biologics sees cash on hand sufficient into 2023 » 16:28
03/04/21
03/04
16:28
03/04/21
16:28
SYN

Synthetic Biologics

$0.58 /

-0.0649 (-10.06%)

Synthetic Biologics…

Synthetic Biologics provided a clinical programs and financial update. The company received Institutional Review Board approval for the SYN-004 Phase 1b/2a clinical trial protocol in allogeneic hematopoietic cell transplant recipients; commenced screening of patients for enrollment of the first of three sequential antibiotic cohorts in the SYN-004 Phase 1b/2a clinical trial in allogeneic HCT recipients. The company's current cash position is approximately $72.6M and sees current cash runway provides funding into 2023 and ability to fully fund Phase 1b/2a clinical trial of SYN-004 and Phase 1 safety studies of SYN-020 intestinal alkaline phosphatase program. The company expects to begin dosing patients in the first antibiotic cohort of the SYN-004 Phase 1b/2a clinical trial during Q1; a topline data readout of the first antibiotic cohort is expected during Q4; to commence first Phase 1 single-ascending-dose study of SYN-020 during Q2, with topline data anticipated during Q3; and expects to commence second Phase 1 multiple-ascending-dose study of SYN-020 during Q3, with topline data anticipated during Q2 2022.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.58 /

-0.0649 (-10.06%)

SYN Synthetic Biologics
$0.58 /

-0.0649 (-10.06%)

10/02/20 Maxim
Synthetic Biologics downgraded to Hold from Buy at Maxim
06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
05/06/20 Alliance Global Partners
Synthetic Biologics price target lowered to $1.25 from $2.25 at Alliance Global
SYN Synthetic Biologics
$0.58 /

-0.0649 (-10.06%)

Over a quarter ago
Hot Stocks
Synthetic Biologics: IRB at Washington University approves trial of SYN-004 » 07:02
12/22/20
12/22
07:02
12/22/20
07:02
SYN

Synthetic Biologics

$0.34 /

-0.014 (-3.99%)

Synthetic Biologics…

Synthetic Biologics announced it has received approval from the Institutional Review Board at Washington University School of Medicine in St. Louis to commence the Phase 1b/2a clinical trial of SYN-004 in allogeneic hematopoietic cell transplant recipients. As a result, the company expects to commence patient enrollment for the Phase 1b/2a clinical trial in the first quarter of 2021.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.34 /

-0.014 (-3.99%)

SYN Synthetic Biologics
$0.34 /

-0.014 (-3.99%)

10/02/20 Maxim
Synthetic Biologics downgraded to Hold from Buy at Maxim
06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
05/06/20 Alliance Global Partners
Synthetic Biologics price target lowered to $1.25 from $2.25 at Alliance Global
SYN Synthetic Biologics
$0.34 /

-0.014 (-3.99%)

Hot Stocks
Synthetic Biologics granted extension of compliance plan by NYSE American » 07:09
11/24/20
11/24
07:09
11/24/20
07:09
SYN

Synthetic Biologics

$0.36 /

+0.004 (+1.11%)

Synthetic Biologics…

Synthetic Biologics announced that on November 23, the NYSE American notified the company that it had been granted an extension until May 25, 2021 to regain compliance with certain continued listing standards as set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.36 /

+0.004 (+1.11%)

SYN Synthetic Biologics
$0.36 /

+0.004 (+1.11%)

10/02/20 Maxim
Synthetic Biologics downgraded to Hold from Buy at Maxim
06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
05/06/20 Alliance Global Partners
Synthetic Biologics price target lowered to $1.25 from $2.25 at Alliance Global
SYN Synthetic Biologics
$0.36 /

+0.004 (+1.11%)

Hot Stocks
Synthetic Biologics engages AGP as advisor to assist in evaluationg options » 07:07
11/16/20
11/16
07:07
11/16/20
07:07
SYN

Synthetic Biologics

$0.34 /

-0.0124 (-3.49%)

Synthetic Biologics…

Synthetic Biologics announced it has engaged A.G.P./Alliance Global Partners to assist the company in exploring and evaluating a range of strategic options. The engagement, which was approved by the Company's Board of Directors, is intended to optimize the company's ability to maximize growth while increasing value for its shareholders. "As part of our ongoing evaluation of our portfolio of assets we have retained A.G.P./Alliance Global Partners to advise us as we explore a range of potential strategic options intended to support our growth initiatives and generate value for our shareholders," said Steven A. Shallcross, Chief Executive and Financial Officer. "We look forward to working with A.G.P./Alliance Global Partners in our efforts to evaluate strategic options, including potentially in-licensing or acquiring assets that may complement our team's deep scientific and operational expertise, our clinical development pipeline, or give us the ability to expand our interests into related areas of clinical development." Synthetic Biologics does not have a defined timeline for the exploration of strategic alternatives and is not confirming that the evaluation will result in any strategic alternative being announced or consummated. Potential strategic alternatives that may be explored or evaluated by the company as part of this process include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions involving the company.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.34 /

-0.0124 (-3.49%)

SYN Synthetic Biologics
$0.34 /

-0.0124 (-3.49%)

10/02/20 Maxim
Synthetic Biologics downgraded to Hold from Buy at Maxim
06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
05/06/20 Alliance Global Partners
Synthetic Biologics price target lowered to $1.25 from $2.25 at Alliance Global
SYN Synthetic Biologics
$0.34 /

-0.0124 (-3.49%)

Earnings
Synthetic Biologics reports Q3 EPS (14c), consensus (17c) » 16:25
11/10/20
11/10
16:25
11/10/20
16:25
SYN

Synthetic Biologics

$0.34 /

+0.0198 (+6.09%)

Cash and cash equivalents…

Cash and cash equivalents as of September 30 totaled $6M, a decrease of $9M from December 31, 2019.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.34 /

+0.0198 (+6.09%)

SYN Synthetic Biologics
$0.34 /

+0.0198 (+6.09%)

10/02/20 Maxim
Synthetic Biologics downgraded to Hold from Buy at Maxim
06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
05/06/20 Alliance Global Partners
Synthetic Biologics price target lowered to $1.25 from $2.25 at Alliance Global
SYN Synthetic Biologics
$0.34 /

+0.0198 (+6.09%)

Downgrade
Synthetic Biologics downgraded to Hold from Buy at Maxim » 13:02
10/02/20
10/02
13:02
10/02/20
13:02
SYN

Synthetic Biologics

$0.31 /

-0.1455 (-32.08%)

Maxim analyst Naureen…

Maxim analyst Naureen Quibria downgraded Synthetic Biologics to Hold from Buy after the company announced that a planned interim futility analysis of the Phase 2b clinical study of SYN-010 concluded that it is unlikely to meet its primary objective by the time enrollment is completed.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.31 /

-0.1455 (-32.08%)

SYN Synthetic Biologics
$0.31 /

-0.1455 (-32.08%)

06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
05/06/20 Alliance Global Partners
Synthetic Biologics price target lowered to $1.25 from $2.25 at Alliance Global
SYN Synthetic Biologics
$0.31 /

-0.1455 (-32.08%)

Hot Stocks
Synthetic Biologics: CSMC to discontinue Phase 2b clinical study of SYN-010 » 07:04
10/02/20
10/02
07:04
10/02/20
07:04
SYN

Synthetic Biologics

$0.47 /

-0.0065 (-1.38%)

Synthetic Biologics…

Synthetic Biologics announced the results of a planned interim futility analysis of the investigator-sponsored Phase 2b clinical study of SYN-010 being conducted by Cedars-Sinai Medical Center. Based on the review of the interim analysis, it was concluded that although SYN-010 was well-tolerated, it is unlikely to meet its primary objective by the time enrollment is completed. As a result, CSMC has agreed to discontinue the trial and will conduct a comprehensive review of the final data set and publish its findings.

ShowHide Related Items >><<
SYN Synthetic Biologics
$0.47 /

-0.0065 (-1.38%)

SYN Synthetic Biologics
$0.47 /

-0.0065 (-1.38%)

06/18/20 Maxim
Synthetic Biologics initiated with a Buy at Maxim
05/06/20 Alliance Global Partners
Synthetic Biologics price target lowered to $1.25 from $2.25 at Alliance Global
SYN Synthetic Biologics
$0.47 /

-0.0065 (-1.38%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.